RADIOBIOLOGICAL STUDIES OF HUMAN HYBRID CELL LINES
人类杂交细胞系的放射生物学研究
基本信息
- 批准号:3178141
- 负责人:
- 金额:$ 17.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1986
- 资助国家:美国
- 起止时间:1986-03-01 至 1992-02-28
- 项目状态:已结题
- 来源:
- 关键词:DNA damage DNA repair HeLa cells acidity /alkalinity athymic mouse bioassay cell bank /registry cell population study cellular oncology cytogenetics fibroblasts gene expression hybrid cells immunologic techniques ionizing radiation morphology neoplasm /cancer genetics oncoproteins radiation carcinogenesis radiation dosage radiation genetics radiation sensitivity radiobiology tumor antigens
项目摘要
The long term objectives of the proposed research are several. The first
is to gain further understanding of the genetic control of the
radiosensitivity of human cells and how the genetic changes which
accompany neoplastic transformation may effect radiosensitivity. The
second is to determine radiation-induced genetic changes associated with
the neoplastic transformation of human cells. The third is to obtain
quantitative information relating to various aspects of radiation-induced
neoplastic transformation of human derived cell lines. The medical
significance of the proposed research is principally to the fields of
radiation carcinogenesis and radiation therapy.
To approach these long term objectives, we will continue our studies with
well characterized non-tumorigenic and tumorigenic human cell hybrid
lines (HeLa x skin fibroblast). Furthermore, we will initiate new
studies with human microcell hybrid lines (HeLa plus a single copy of a
human skin fibroblast chromosome, initially chromosome 11 which has been
shown to suppress the tumorigenicity of HeLa cells).
The rationale for the Specific Aims for the proposed funding period is
based on our studies to date. These aims include (1) examining the cell
cycle dependency of radiosensitivity and DNA damage induction and repair
of both non-tumorigenic and tumorigenic hybrid cells, (2) examining
contribution of PLDR and SLDR to cell survival and neoplastic
transformation for non-tumorigenic cells treated with fractionated and
low dose-rate radiation and (3) isolating and characterizing various
properties radiation-induced neoplastic cells (including probing for loss
of tumor-suppressor gene). Standard methodologies as well as those
either developed or being developed in the laboratories of the P.I. and
Co-P.I. will be used. Cell survival will be assessed by colony forming
ability, DNA damage by alkali and neutral elution; neoplastic
transformation by immunoperoxidase assay of expression of tumor
associated antigen, by loss of suppressor gene by RFLP analysis, and by
ability of cells to grow tumors when injected into nude mice.
拟议研究的长期目标有几个。 第一
是为了更深入地了解
人体细胞的辐射敏感性以及遗传变化,
伴随的肿瘤转化可能影响放射敏感性。 的
第二,确定辐射引起的遗传变化,
人类细胞的肿瘤性转化。 三是获得
与辐射引起的各种问题有关的定量资料
人源细胞系的肿瘤转化。 医疗
建议的研究的意义主要是对领域的
放射致癌和放射治疗。
为达致这些长远目标,我们会继续进行研究,
充分表征的非致瘤性和致瘤性人细胞杂交体
细胞系(HeLa x皮肤成纤维细胞)。 此外,我们将启动新的
用人微细胞杂交系(HeLa加上一个单拷贝的
人皮肤成纤维细胞染色体,最初是染色体11,
显示抑制HeLa细胞的致瘤性)。
建议资助期内的具体目标的理据如下
根据我们迄今为止的研究 这些目标包括(1)检查细胞
辐射敏感性和DNA损伤诱导和修复的周期依赖性
非致瘤性和致瘤性杂交细胞,(2)检查
PLDR和SLDR对细胞存活和肿瘤形成的贡献
用分级分离的和
低剂量率辐射和(3)分离和表征各种
辐射诱导的肿瘤细胞(包括探测损失)
肿瘤抑制基因)。 标准方法以及
无论是在私人研究所的实验室里开发的还是正在开发的。和
Co-P.I.将用于 将通过集落形成评估细胞存活
能力,碱和中性洗脱的DNA损伤;肿瘤性
肿瘤表达的免疫过氧化物酶测定转化
相关抗原,通过RFLP分析抑制基因的丢失,以及通过
当注射到裸鼠体内时,细胞生长肿瘤的能力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN L REDPATH其他文献
JOHN L REDPATH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN L REDPATH', 18)}}的其他基金
RADIOBIOLOGICAL STUDIES OF HUMAN HYBRID CELL LINES
人类杂交细胞系的放射生物学研究
- 批准号:
3178133 - 财政年份:1986
- 资助金额:
$ 17.14万 - 项目类别:
RADIOBIOLOGICAL STUDIES OF HUMAN HYBRID CELL LINES
人类杂交细胞系的放射生物学研究
- 批准号:
3178140 - 财政年份:1986
- 资助金额:
$ 17.14万 - 项目类别:
RADIOBIOLOGICAL STUDIES OF HUMAN HYBRID CELL LINES
人类杂交细胞系的放射生物学研究
- 批准号:
3178134 - 财政年份:1986
- 资助金额:
$ 17.14万 - 项目类别:
RADIOBIOLOGICAL STUDIES OF HUMAN HYBRID CELL LINES
人类杂交细胞系的放射生物学研究
- 批准号:
3178139 - 财政年份:1986
- 资助金额:
$ 17.14万 - 项目类别:
相似海外基金
DNA repair pathway coordination during damage processing
损伤处理过程中 DNA 修复途径的协调
- 批准号:
10748479 - 财政年份:2024
- 资助金额:
$ 17.14万 - 项目类别:
CAREER: Mechanisms and consequences of epigenome-recruited DNA repair systems in plants
职业:植物中表观基因组招募的 DNA 修复系统的机制和后果
- 批准号:
2338236 - 财政年份:2024
- 资助金额:
$ 17.14万 - 项目类别:
Continuing Grant
Multifaceted regulation of the DNA repair machinery and suppression of aberrant transcription by telomere proteins
DNA 修复机制的多方面调控和端粒蛋白异常转录的抑制
- 批准号:
2246561 - 财政年份:2023
- 资助金额:
$ 17.14万 - 项目类别:
Standard Grant
Elucidation of the molecular link between DNA repair and mitochondrial nucleic acid metabolism
阐明DNA修复和线粒体核酸代谢之间的分子联系
- 批准号:
23K07078 - 财政年份:2023
- 资助金额:
$ 17.14万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Structural studies for understanding the mechanism of DNA repair in chromatin
了解染色质 DNA 修复机制的结构研究
- 批准号:
23H05475 - 财政年份:2023
- 资助金额:
$ 17.14万 - 项目类别:
Grant-in-Aid for Scientific Research (S)
Biochemistry of Eukaryotic Replication Fork and DNA Repair
真核复制叉的生物化学和 DNA 修复
- 批准号:
10550045 - 财政年份:2023
- 资助金额:
$ 17.14万 - 项目类别:
Modeling the Responsiveness of Sensitive Populations to Genotoxic Agents Using DNA Repair Inhibitors
使用 DNA 修复抑制剂模拟敏感人群对基因毒性药物的反应性
- 批准号:
10734425 - 财政年份:2023
- 资助金额:
$ 17.14万 - 项目类别:
A role of balanced sex hormone in DNA repair in human melanocytes
平衡性激素在人类黑素细胞 DNA 修复中的作用
- 批准号:
10666307 - 财政年份:2023
- 资助金额:
$ 17.14万 - 项目类别:
Natural products inhibitors targeting homology-directed DNA repair for cancer therapy
针对癌症治疗的同源定向 DNA 修复的天然产物抑制剂
- 批准号:
10651048 - 财政年份:2023
- 资助金额:
$ 17.14万 - 项目类别: